What Lifeline Biotechnologies does

Lifeline Biotechnologies, Inc. is a publicly traded medical technology company (otcpink:LLBO) headquartered in Reno, Nevada, founded in 1981. Per its firmographic profile, the company develops diagnostic equipment intended for the prevention, early diagnosis, and rapid assessment of medical conditions — though specific products, indications, technical architecture, and regulatory clearances are not disclosed in the available materials. The firm operates with a lean leadership team of Jim Holmes (President & CEO) and Fred V. Schiemann (CFO), and employs between 101 and 250 people.

The company's commercial mechanics are not detailed in the input: no revenue, pricing, distribution channel, or customer information has been disclosed, and the only documented funding event is a $200,000 round in October 2009 from unnamed investors. In May 2025, Lifeline acquired GlobalOdds for an undisclosed sum, which represents the most significant recent strategic event and suggests a directional pivot or diversification into sports betting/odds technology — a notable departure from the legacy diagnostic equipment thesis and one that warrants further diligence. The input also contains material data quality concerns: the company's own website (lbti.com) appears to display content for an unrelated Chinese boron-lithium chemical manufacturer, and the financial figures supplied show implausible multi-trillion-dollar values that are inconsistent with a small-cap OTC medtech firm and should be treated as data artifacts rather than company facts.

Name

Lifeline Biotechnologies

Website

https://lbti.com

Company type

Private

Founded year

1981

Headcount range

101–250 employees

Short description

Lifeline Biotechnologies is a publicly traded Reno, Nevada–based medical technology company (founded 1981, otcpink:LLBO) developing diagnostic equipment for prevention and early diagnosis, which in May 2025 acquired GlobalOdds in a notable diversification move.

Ownership category

akta.pro rank

Headquarters

HQ city

Reno

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Core offering

Lifeline Biotechnologies, Inc. is a medical technology company that develops diagnostic equipment intended for the prevention, early diagnosis, and rapid clinical assessment of disease. The company's offerings are positioned as devices used by healthcare providers in diagnostic workflows.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Bio-Rad Laboratories: Manufactures clinical diagnostics instruments and life science research products. Comparable as a developer of diagnostic equipment serving clinical and research customers.
• Hologic: Major diagnostic and medical device company with broad portfolios in women's health, diagnostics, and surgical solutions. Comparable as a diagnostic equipment developer and the kind of large incumbent that could license or acquire Lifeline's IP.
• Qiagen: Provider of sample-prep and molecular diagnostic technologies. Comparable as a diagnostic equipment / consumables company with research and clinical customers.
• QuidelOrtho: Diagnostics-focused public company producing immunoassay and molecular diagnostic equipment. Operates in the same diagnostic-device end market Lifeline claims to serve.
• Cepheid (Danaher): Developer of molecular diagnostic systems (GeneXpert). Directly comparable category — diagnostic instruments for early and rapid disease detection.
• Abbott Diagnostics: Division of Abbott producing a wide range of in-vitro diagnostic instruments and rapid tests. Represents a comparable large-scale diagnostic equipment business model.

Emerging players

• Exact Sciences: Diagnostics company focused on early cancer detection using proprietary platforms. Comparable in mission (early diagnosis, prevention-oriented testing) even if channel mix differs.

Direct peers

• GenMark Diagnostics (Roche): Developed molecular diagnostic panels and instruments (now part of Roche). Closely aligned as a smaller diagnostic-equipment developer that was eventually acquired.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifeline Biotechnologies